Grants and Contributions:
Title:
COVID-19 Phase 1 SAD/MAD FIH Clinical Trial of AV-001
Agreement Number:
965762
Agreement Value:
$2,849,345.00
Agreement Date:
Nov 1, 2020 - Feb 28, 2023
Description:
Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with severe COVID-19 disease. The phase 1 study is the first-in-human study designed to demonstrated safety and tolerability of AV-001 in heathy subjects prior to testing in severely ill patients with COVID-19 disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5T 1X5
Reference Number:
172-2020-2021-Q4-965762
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
833657133
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 334 days.
Amendment Date
Apr 8, 2022
Recipient's Legal Name:
Vasomune Therapeutics Inc.
Federal Riding Name:
Spadina--Fort York
Federal Riding Number:
35101
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: